Ursula Wiedermann

Ursula Wiedermann (born 5 August 1965) is an Austrian medical scientist who has made significant contributions in the field of allergies and of cancer immunotherapy. She is currently Professor of Vaccinology at the Medical University of Vienna. Wiedermann's work in the field of B cell peptide vaccines led to the creation of HER-Vaxx, an immunotherapy for the treatment of HER-2-positive cancers. This vaccine is currently being taken into mid-stage clinical development in gastric cancer by the biotech company Imugene, where Wiedermann is Chief Scientific Officer. Provided by Wikipedia